Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 15;148(8):1895-1909.
doi: 10.1002/ijc.33457. Epub 2021 Jan 9.

Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility

Affiliations

Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility

Christine Lonjou et al. Int J Cancer. .

Abstract

Single-nucleotide polymorphisms (SNPs) in over 180 loci have been associated with breast cancer (BC) through genome-wide association studies involving mostly unselected population-based case-control series. Some of them modify BC risk of women carrying a BRCA1 or BRCA2 (BRCA1/2) mutation and may also explain BC risk variability in BC-prone families with no BRCA1/2 mutation. Here, we assessed the contribution of SNPs of the iCOGS array in GENESIS consisting of BC cases with no BRCA1/2 mutation and a sister with BC, and population controls. Genotyping data were available for 1281 index cases, 731 sisters with BC, 457 unaffected sisters and 1272 controls. In addition to the standard SNP-level analysis using index cases and controls, we performed pedigree-based association tests to capture transmission information in the sibships. We also performed gene- and pathway-level analyses to maximize the power to detect associations with lower-frequency SNPs or those with modest effect sizes. While SNP-level analyses identified 18 loci, gene-level analyses identified 112 genes. Furthermore, 31 Kyoto Encyclopedia of Genes and Genomes and 7 Atlas of Cancer Signaling Network pathways were highlighted (false discovery rate of 5%). Using results from the "index case-control" analysis, we built pathway-derived polygenic risk scores (PRS) and assessed their performance in the population-based CECILE study and in a data set composed of GENESIS-affected sisters and CECILE controls. Although these PRS had poor predictive value in the general population, they performed better than a PRS built using our SNP-level findings, and we found that the joint effect of family history and PRS needs to be considered in risk prediction models.

Keywords: association study; familial breast cancer; single-nucleotide polymorphism; systems biology.

PubMed Disclaimer

Conflict of interest statement

Dr P. Pujol is a consultant for AstraZeneca, Pfizer, Roche, MSD, Exact Sciences, Abbvie, OncoDNA, Takeda and Novartis. He received research funding from AstraZeneca, Pfizer and Novartis. The other authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Miami plot of single‐nucleotide polymorphism (SNP) association with breast cancer. A, Results of the case‐control analysis. B, Results of the family‐based association test. −log10 P values for SNP associations are plotted against the genomic coordinates (hg19). The red lines indicate the 10−5 threshold. Green points denote SNPs showing suggestive association with breast cancer [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
Physical interactions among proteins encoded by genes associated with breast cancer or genes in the associated intervals. A, Protein‐protein interaction (PPI) network obtained with genes located within the 18 loci from the single‐nucleotide polymorphism (SNP)‐level analysis. B, PPI network obtained with the 112 top genes from the gene‐level analysis. C, PPI network obtained with the input gene list combining input lists from Figures 2A and 2B [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117‐1130. - PMC - PubMed
    1. Domchek SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene. 2006;25:5825‐5831. - PubMed
    1. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917‐921. - PubMed
    1. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2‐interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165‐167. - PMC - PubMed
    1. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia‐telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38:873‐875. - PubMed

Publication types

MeSH terms

Supplementary concepts